BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29225105)

  • 1. Interpretation of B-type natriuretic peptides in the era of angiotensin receptor-neprilysin inhibitors.
    Bettencourt P; Fonseca C; Franco F; Andrade A; Brito D
    Rev Port Cardiol; 2017 Dec; 36(12):881-884. PubMed ID: 29225105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
    Myhre PL; Vaduganathan M; Claggett B; Packer M; Desai AS; Rouleau JL; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2019 Mar; 73(11):1264-1272. PubMed ID: 30846338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of natriuretic peptides to assess and manage patients with heart failure receiving angiotensin receptor blocker/neprilysin inhibitor therapy.
    Maisel AS; Daniels LB; Anand IS; McCullough PA; Chow SL
    Postgrad Med; 2018 Apr; 130(3):299-307. PubMed ID: 29596012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The relationship between natriuretic peptides and neprilysin pathways: the clinical simplification against the complexity of biological systems].
    Di Tano G; Clerico A
    G Ital Cardiol (Rome); 2017 Feb; 18(2):95-100. PubMed ID: 28398362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
    Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
    J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring B-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge?
    Lippi G; Sanchis-Gomar F
    Int J Cardiol; 2016 Sep; 219():111-4. PubMed ID: 27317994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis.
    Vasquez N; Carter S; Grodin JL
    Curr Heart Fail Rep; 2020 Jun; 17(3):67-76. PubMed ID: 32394149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BNP and NT-proBNP Interpretation in the Neprilysin Inhibitor Era.
    Sbolli M; deFilippi C
    Curr Cardiol Rep; 2020 Sep; 22(11):150. PubMed ID: 32951154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Molar Ratio of N-terminal pro-B-type Natriuretic Peptide/B-type Natriuretic Peptide for Heart Failure-related Events in Stable Outpatients with Cardiovascular Risk Factors.
    Suzuki S; Sugiyama S
    Intern Med; 2018 Sep; 57(18):2621-2630. PubMed ID: 29709934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-Terminal B-type Natriuretic Peptide in Heart Failure.
    Richards AM
    Heart Fail Clin; 2018 Jan; 14(1):27-39. PubMed ID: 29153198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting N-Terminal Pro-Brain Natriuretic Peptide in Older Versus Younger Acute Decompensated Heart Failure Patients.
    Stienen S; Salah K; Eurlings LW; Bettencourt P; Pimenta JM; Metra M; Bayes-Genis A; Verdiani V; Bettari L; Lazzarini V; Tijssen JP; Pinto YM; Kok WE
    JACC Heart Fail; 2016 Sep; 4(9):736-45. PubMed ID: 27395353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study.
    Kimmoun A; Cotter G; Davison B; Takagi K; Addad F; Celutkiene J; Chioncel O; Solal AC; Diaz R; Damasceno A; Duengen HD; Filippatos G; Goncalvesova E; Merai I; Metra M; Ponikowski P; Privalov D; Sliwa K; Sani MU; Voors AA; Shogenov Z; Mebazaa A
    Eur J Heart Fail; 2019 Nov; 21(11):1459-1467. PubMed ID: 31423712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin: The N-Terminal Part Does Matter.
    Semenov AG; Katrukha AG
    Clin Chem; 2016 Apr; 62(4):617-22. PubMed ID: 26864319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New issues on measurement of B-type natriuretic peptides.
    Clerico A; Zaninotto M; Passino C; Plebani M
    Clin Chem Lab Med; 2017 Nov; 56(1):32-39. PubMed ID: 28809748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly Inhibit Circulating Neprilysin Activity in Heart Failure.
    Vodovar N; Séronde MF; Laribi S; Gayat E; Lassus J; Januzzi JL; Boukef R; Nouira S; Manivet P; Samuel JL; Logeart D; Cohen-Solal A; Richards AM; Launay JM; Mebazaa A;
    JACC Heart Fail; 2015 Aug; 3(8):629-36. PubMed ID: 26251090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Neprilysin vs NT-proBNP.
    Bayes-Genis A; Barallat J; Galán A; de Antonio M; Domingo M; Zamora E; Gastelurrutia P; Vila J; Peñafiel J; Gálvez-Montón C; Lupón J
    Rev Esp Cardiol (Engl Ed); 2015 Dec; 68(12):1075-84. PubMed ID: 26297179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.
    Wolsk E; Claggett B; Pfeffer MA; Diaz R; Dickstein K; Gerstein HC; Lawson FC; Lewis EF; Maggioni AP; McMurray JJV; Probstfield JL; Riddle MC; Solomon SD; Tardif JC; Køber L
    J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28554908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial).
    Nadruz W; Claggett BL; McMurray JJ; Packer M; Zile MR; Rouleau JL; Desai AS; Swedberg K; Lefkowitz M; Shi VC; Prescott MF; Solomon SD
    Circulation; 2016 Nov; 134(22):1785-1787. PubMed ID: 27895026
    [No Abstract]   [Full Text] [Related]  

  • 20. The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management.
    Ibrahim N; Januzzi JL
    Expert Rev Cardiovasc Ther; 2015; 13(9):1017-30. PubMed ID: 26198476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.